Practical aspects of the using levosalbutamol in adults and children: Resolution of the Council of Experts-Reference-Cited by-同舟云学术

Practical aspects of the using levosalbutamol in adults and children: Resolution of the Council of Experts

Published:2024-07-16 Issue:4 Volume:34 Page:576-584
ISSN:2541-9617
Container-title:PULMONOLOGIYA
language:
Short-container-title:Pulʹmonologiâ (Mosk.)

Author:

Avdeev S. N.¹^ORCID,Namazova-Baranova L. S.²^ORCID,Aisanov Z. R.³^ORCID,Antonov V. N.⁴^ORCID,Arkhipov V. V.⁵^ORCID,Borodulina E. A.⁶^ORCID,Vizel A. A.⁷^ORCID,Vishneva E. A.⁸^ORCID,Demko I. V.⁹^ORCID,Emelyanov A. V.¹⁰^ORCID,Ignatova G. L.⁴^ORCID,Kurbacheva O. M.¹¹^ORCID,Leshсhenko I. V.¹²^ORCID,Nenasheva N. M.⁵^ORCID

Affiliation:

1. Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); Federal State Budgetary Institution “Pulmonology Scientific Research Institute” under Federal Medical and Biological Agency of Russian Federation

2. Federal State Autonomous Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University” of the Ministry of Health of the Russian Federation; Research Institute of Pediatrics and Children’s Health, Scientific and Clinical Center No.2, Federal State Budgetary Scientific Institution “Petrovsky National Research Centre of Surgery”

3. Federal State Autonomous Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University” of the Ministry of Health of the Russian Federation

4. Federal State Budgetary Educational Institution of Higher Education “South-Ural State Medical University” of the Ministry of Healthcare of the Russian Federation

5. Federal State Budgetary Educational Institution of Additional Professional Education “Russian Medical Academy of Continuous Professional Education”, Ministry of Health of Russia

6. Federal State Budgetary Educational Institution of Higher Education “Samara State Medical University” of the Ministry of Healthcare of the Russian Federation

7. Federal State Budgetary Educational Institution of Higher Education Kazan State Medical University of the Ministry of Health of the Russian Federation

8. Research Institute of Pediatrics and Children’s Health, Scientific and Clinical Center No.2, Federal State Budgetary Scientific Institution “Petrovsky National Research Centre of Surgery”; Federal State Autonomous Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University” of the Ministry of Health of the Russian Federation

9. Federal State Budgetary Educational Institution of Higher Education “Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky”

10. Federal State Budgetary Educational Institution of Higher Education “North-Western State Medical University named after I.I. Mechnikov”, Ministry of Health of the Russian Federation

11. National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia; Federal state budgetary educational institution of higher education “Russian University of Medicine” of the Ministry of Health of the Russian Federation

12. Federal State Budget Educational Institution of Higher Education “Ural State Medical University” of the Ministry of Health of the Russian Federation; Ural Federal Research Institute of Phthisiology and Pulmonology – A Branch of National Medical Research Center for Phthisiology, Pulmonology and Infectious Diseases, Healthcare Ministry of Russia; Limited Liability Company “Novaya bol’nitsa” Clinical Association

Abstract

The purpose of publishing the resolution of the Interdisciplinary Council of Experts in the fields of pulmonology, allergology, pediatrics, and clinical pharmacology was to discuss the effectiveness and safety of a new short-acting β2-adrenergic receptor agonist in the Russian Federation – levosalbutamol. The Interdisciplinary Council of Experts in the fields of pulmonology, allergology, pediatrics, and clinical pharmacology took place on March 19, 2024 in Moscow. Results. According to the research results, the following advantages of using levosalbutamol have been demonstrated: the affinity for β2-adrenergic receptors is 2 times higher compared to salbutamol; the drug affects the sensitization of β2 receptors to a lesser degree; levosalbutamol does not cause increased airway hyperresponsiveness; levosalbutamol has a more pronounced anti-inflammatory effect; greater safety for the cardiovascular system was noted. Conclusion. According to the presented data, the inclusion of levosalbutamol in clinical guidelines for asthma (age category “children, adults”) and chronic obstructive pulmonary disease (age category “adults”) is justified.

Publisher

Scientific and Practical Reviewed Journal Pulmonology

Reference40 articles.

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2023 GINA Report. Available at: https://ginasthma.org/2023-gina-main-report/ [Accessed November 21, 2023].

2. World Health Organization. Asthma. Available at: https://www.who.int/news-room/fact-sheets/detail/asthma [Accessed November 21, 2023].

3. Bystritskaya E.V., Bilichenko T.N. [The review of the bronchial asthma morbidity in the population of the Russian Federation]. Pul'monologiya. 2022; 32 (5): 651–660. DOI: 10.18093/0869-0189-2022-32-5-651-660 (in Russian).

4. Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. [Federal guidelines on diagnosis and treatment of bronchial asthma]. Pul'monologiya. 2022; 32 (3): 393–447. DOI: 10.18093/0869-0189-2022-32-3-393-447 (in Russian).

5. Drugbank online. Salbutamol. Available at: https://go.drugbank.com/drugs/DB01001 [Accessed: November 21, 2023].